# PepGen

Type: Company (PEPG)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/pepgen
Canonical HTML page: https://getbiobrief.com/entity/pepgen

## Recent coverage (2 stories)

### OmniAb and PepGen Reveal 2025 Financials and 2026 Clinical Roadmaps
2026-03-05 05:51:06 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

OmniAb and PepGen have released their full-year 2025 financial results, highlighting a period of operational scaling and clinical advancement. While OmniAb continues to expand its antibody discovery ecosystem, PepGen is entering a critical phase with key data readouts expected in 2026 for its neuromuscular pipeline.
Full story: https://getbiobrief.com/story/omniab-pepgen-q4-2025-earnings-analysis

### GeneDx and PepGen Set for Critical Monday Earnings Amid Genomics Pivot
2026-02-21 07:54:44 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

GeneDx (WGS) and PepGen (PEPG) are scheduled to release financial results on Monday, marking a pivotal moment for the clinical genomics and neuromuscular therapeutic sectors. Investors are looking for GeneDx to demonstrate a sustainable path to profitability through its whole genome sequencing volume, while PepGen's update will focus on its clinical pipeline and cash position.
Full story: https://getbiobrief.com/story/genedx-pepgen-earnings-preview-clinical-genomics

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.